Legal & General Group PLC Pmv Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.94 - $6.27 $3,829 - $6,094	-972 Reduced 21.89%	3,468 $21,000
Q1 2023 May 15, 2023	SELL	$4.77 - $9.16 $19,275 - $37,015	-4,041 Reduced 47.65%	4,440 $21,000
Q3 2022 Nov 14, 2022	BUY	$11.4 - $17.18 $4,092 - $6,167	359 Added 4.42%	8,481 $101,000
Q2 2022 Aug 22, 2022	BUY	$9.23 - $22.43 $9,737 - $23,663	1,055 Added 14.93%	8,122 $116,000
Q1 2022 May 16, 2022	SELL	$14.86 - $23.55 $133 - $211	-9 Reduced 0.13%	7,067 $147,000
Q4 2021 Feb 14, 2022	BUY	$19.99 - $30.24 $1,199 - $1,814	60 Added 0.86%	7,076 $164,000
Q3 2021 Nov 15, 2021	BUY	$26.84 - $36.58 $104,407 - $142,296	3,890 Added 124.44%	7,016 $209,000
Q2 2021 Aug 12, 2021	BUY	$28.01 - $36.01 $47,532 - $61,108	1,697 Added 118.75%	3,126 $107,000
Q1 2021 May 17, 2021	SELL	$30.66 - $49.5 $1,379 - $2,227	-45 Reduced 3.05%	1,429 $47,000
Q4 2020 Feb 12, 2021	SELL	$31.86 - $61.51 $1.43 Million - $2.76 Million	-44,826 Reduced 96.82%	1,474 $90,000
Q3 2020 Nov 13, 2020	BUY	$35.5 - $38.0 $1.64 Million - $1.76 Million	46,300 New	46,300 $1.73 Million

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.